Results 11 to 20 of about 1,420 (176)

Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension [PDF]

BMC Neurology, 2017
Background Droxidopa, a prodrug of norepinephrine, was approved for treatment of neurogenic orthostatic hypotension (nOH) due to primary autonomic disorders based on 3 randomized double-blind studies.
Italo Biaggioni, L. Arthur Hewitt, Gerald J. Rowse, Horacio Kaufmann   +3 more
doaj   +3 more sources

Belly dancer syndrome improved by withdrawal of droxidopa and amantadine

Clinical Case Reports, 2023
Key Clinical Message A man hospitalized for cerebral infarction developed drug‐induced belly dancer syndrome, which improved after withdrawal of droxidopa and amantadine.
Mihiro Kaga, Hiroyoshi Ueda, Chika Sunagawa, Masashi Oe, Atsushi Shima, Nobuyasu Matsukawa, Takeshi Ueda   +6 more
doaj   +3 more sources

Fix or Adapt? Rethinking the Management of Complex Autonomic Dysfunction in an Older Adult Following Orthopedic Surgery. [PDF]

Geriatr Gerontol Int
Geriatrics &Gerontology International, Volume 25, Issue 12, Page 1962-1964, December 2025.
De Louche CD, Palliyage S.
europepmc   +2 more sources

Postprandial Hypotension-Methods for the Evaluation and Management. [PDF]

Geriatr Gerontol Int
Postprandial hypotension (PPH) is highly prevalent in older patients; however, its diagnosis remains challenging due to the absence of a consensus guideline for diagnostic criteria. Lifestyle modification is the first‐line management, taking into account the pathophysiology underlying PPH and the coexisting conditions of orthostatic hypotension and ...
Ishikawa J, Toba A, Futami S, Harada K.
europepmc   +2 more sources

Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report

Journal of Medical Case Reports, 2020
Background Droxidopa is an oral treatment for the stepwise treatment of neurogenic orthostatic hypotension from autonomic dysfunction. It has been shown to be useful predominantly with neurogenic orthostatic hypotension secondary to Parkinson’s disease ...
Annie H. Ho, Christopher W. Kinter, John Wight, Anudeep R. Neelam, David Krakow   +4 more
doaj   +1 more source

L-DOPA and Droxidopa: From Force Field Development to Molecular Docking into Human β₂-Adrenergic Receptor

Life, 2022
The increasing interest in the molecular mechanism of the binding of different agonists and antagonists to β2-adrenergic receptor (β2AR) inactive and active states has led us to investigate protein–ligand interactions using molecular docking calculations.
Andrea Catte, Akash Deep Biswas, Giordano Mancini, Vincenzo Barone   +3 more
doaj   +1 more source

Combination therapy of midodrine and droxidopa for refractory hypotension in heart failure with preserved ejection fraction per a pharmacist’s proposal: a case report

Journal of Pharmaceutical Health Care and Sciences, 2021
Background Patients with chronic heart failure (CHF) are often treated using many diuretics for symptom relief; however, diuretic use may have to continue despite hypotension development in these patients.
Yuki Asai, Tomoaki Sato, Daisuke Kito, Takanori Yamamoto, Iwao Hioki, Yasuhisa Urata, Yasuharu Abe   +6 more
doaj   +1 more source

Orthostatic hypotension: An overlooked but clinically decisive entity

Journal of the Indian Academy of Geriatrics, 2022
Orthostatic hypotension (OH) is defined as a drop of >20 mm Hg of systolic or >10 mm Hg of diastolic blood pressure (BP) within 3 min of standing from lying position. It is a common geriatric syndrome caused by impaired orthostatic response of BP.
Gunja Jain, Sunny Singhal, Laxmi Kant Goyal, Ajay Mathur   +3 more
doaj   +1 more source

Emerging pharmacological strategies for the treatment of fibromyalgia [PDF]

, 2017
Fibromyalgia (FM) has been described as a chronic clinical condition related to multisensory hypersensitivity presenting with a complex of symptoms dominated by chronic widespread pain associated with the existence of a range of co-morbidities, such
Lawson, Kim
core   +1 more source

Insight into Tyrosine-Containing Pharmaceuticals as Potential Inhibitors of SARS-CoV-2 3CL^pro and NSP16: Structural Analysis, Docking Studies, Molecular Dynamics Simulations, and Density Functional Theory Investigations

Chemistry, 2023
Tyrosine-containing pharmaceuticals’ (TPh) potential to inhibit SARS CoV-2 3-chymotrypsin-like proteases (3CLpro) and nonstructural protein 16 (NSP16) has been explored using docking studies, molecular dynamics simulations, and density functional theory.
Mohamed R. Elamin, Tarek A. Yousef, Amin O. Elzupir   +2 more
doaj   +1 more source